CRISPR Therapeutics Announces Poster Presentation at the American Association for Cancer Research 2022 Annual Meeting

Rhea-AI Summary

CRISPR Therapeutics (Nasdaq: CRSP) will present an e-poster at the AACR 2022 Annual Meeting from April 8-13, 2022, highlighting its innovative cancer immunotherapy research. The presentation titled “CBLB, CISH and CD70 multiplexed gene knockout with CRISPR/Cas9 enhances cytotoxicity of CD70-CAR NK cells” is set for April 8, 2022. This research emphasizes the potential of CRISPR/Cas9 technology in advancing cancer treatments. As a leader in gene editing, CRISPR Therapeutics aims to develop transformative therapies for serious diseases, collaborating with major firms like Bayer and Vertex Pharmaceuticals.

Positive

• Presentation of innovative research at AACR 2022 may enhance visibility.
• Focus on CRISPR/Cas9 technology positions the company as a leader in gene editing.
• Strategic collaborations with Bayer and Vertex Pharmaceuticals can accelerate growth.

Negative

• None.

ZUG, Switzerland and CAMBRIDGE, Mass., March 08, 2022 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that it will present an e-poster at the American Association for Cancer Research (AACR) 2022 Annual Meeting, taking place April 8-13, 2022, at the Ernest N. Morial Convention Center in New Orleans, Louisiana, and online.

Title: CBLB, CISH and CD70 multiplexed gene knockout with CRISPR/Cas9 enhances cytotoxicity of CD70-CAR NK cells and provides greater resistance to TGF-β for cancer immunotherapy
Session Title: Preclinical Immunotherapy
Session Category: Immunology
Abstract Number: 5512, e-poster
Date and Time: Friday, April 8, 2022, 1:00 p.m. via the AACR website, www.aacr.org

Presented jointly with Nkarta, Inc.

About CRISPR Therapeutics
CRISPR Therapeutics is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with leading companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.

CRISPR THERAPEUTICS^® word mark and design logo are trademarks and registered trademarks of CRISPR Therapeutics AG. All other trademarks and registered trademarks are the property of their respective owners.

Investor Contact:
Susan Kim
+1-617-307-7503
susan.kim@crisprtx.com

Media Contact:
Rachel Eides
+1-617-315-4493
rachel.eides@crisprtx.com

FAQ

What is CRISPR Therapeutics presenting at AACR 2022?

CRISPR Therapeutics is presenting an e-poster on cancer immunotherapy research using CRISPR/Cas9 technology.

When is CRISPR Therapeutics' presentation scheduled?

The presentation is scheduled for April 8, 2022.

What is the title of the e-poster being presented by CRISPR Therapeutics?

The title is 'CBLB, CISH and CD70 multiplexed gene knockout with CRISPR/Cas9 enhances cytotoxicity of CD70-CAR NK cells.'

What technology does CRISPR Therapeutics use in its research?

CRISPR Therapeutics uses CRISPR/Cas9 technology in its research and development.

Who are CRISPR Therapeutics' partners in its research?

CRISPR Therapeutics collaborates with companies like Bayer and Vertex Pharmaceuticals.